45434-73-9

Usage

Uses

Used in Organic Synthesis:
3,4-Furandiamine, tetrahydro-, (3S,4S)-(9CI) is used as a building block in organic synthesis for the creation of other organic compounds. Its unique structure and functional groups make it a valuable component in the synthesis of various organic molecules.
Used in Research and Experimental Settings:
In the field of scientific research, 3,4-Furandiamine, tetrahydro-, (3S,4S)-(9CI) serves as a key compound for studying its properties and potential applications. Researchers use it to explore its reactivity, stability, and interactions with other chemical entities, which can contribute to the advancement of organic chemistry and related disciplines.
Used in Pharmaceutical Development (if applicable):
While the provided materials do not explicitly mention pharmaceutical applications, the compound's amine groups and unique structure could potentially be harnessed in the development of new pharmaceutical agents. Further research would be required to determine its suitability and efficacy in this context.
Used in Chemical Industry (if applicable):
Similarly, the potential use of 3,4-Furandiamine, tetrahydro-, (3S,4S)-(9CI) in the chemical industry is not detailed in the provided materials. However, given its structural features, it could be employed in the production of specialty chemicals, materials, or intermediates for various applications. Additional studies would be needed to establish its role and benefits in this industry.

Upstream product

• 167937-18-0 (S,S)-trans-3,4-diazidotetrahydrofuran 

Downstream Products

• 1330763-30-8 (4-aminotetrahydrofuran-3-yl)carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS

The invention provides certain 3-pyridyl carboxamide-containing compounds of the Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

Diamine derivatives

A compound represented by the general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

DIAMINE DERIVATIVES

A compound represented by the general formula (1):Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Synthesis of C2 symmetric primary vicinal diamines. Double stereospecific Mitsunobu reaction of the heterocyclic diols derived from tartaric acid

Homochiral 1-alkyl-3,4-dihydroxypyrrolidines, (S,S)- and (R,R)-5 were obtained by cyclization and reduction of both enantiomers of (+)- and (-)-tartaric acid, respectively. Also (S,S)-3,4-dihydroxytetrahydrofurane 6 was prepared from (+)-diethyl tartrate. All these heterocyclic vic-diols underwent twofold Mitsunobu reaction (Ph3P/DEA/HN3) followed by catalytic hydrogenation forming stereospecifically the corresponding primary vicinal diamines (R,R)-, (S,S)-2 and (R,R)-3. The absolute configuration of diamines 2, 3 was established by the exciton-coupling CD spectra of their N,N'-diphthaloyl derivatives.